Abstral Approval History
- FDA approved: Yes (First approved January 7th, 2011)
- Brand name: Abstral
- Generic name: fentanyl
- Dosage form: Sublingual Tablets
- Company: Orexo AB
- Treatment for: Pain
Abstral (fentanyl) is a sublingual opioid analgesic indicated for the management of breakthrough pain in cancer patients.
Development History and FDA Approval Process for Abstral
|Jan 10, 2011||FDA Approval for Abstral (Fentanyl) Sublingual Tablets|
|Sep 7, 2010||Update on the FDA review for Abstral|
|Jun 15, 2010||Orexo confirms Abstral PDUFA date update|
|Oct 6, 2009||Orexo confirms FDA acceptance of Abstral filing|
|Aug 6, 2009||Abstral NDA submitted to the FDA for approval in the USA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.